CORYNANTHE YOHIMBE BARK EXTRACT.

Given the explicit lack of clinical trials on the bark extract for any health condition, including topical efficacy, combined with significant systemic safety concerns, its inclusion in skincare formulations likely falls into 'dusting'. Products may contain this ingredient at concentrations insufficient to elicit any purported effect, or for marketing claims that lack scientific validation, prioritizing avoidance of severe adverse effects over proven benefits.

The European Food Safety Authority (EFSA) has expressed concerns regarding potential harm to human health from yohimbe bark and its preparations, citing strong pharmacological and/or psychoactive effects, despite some scientific uncertainty. Consequently, supplements containing yohimbe bark are banned in several countries, including Canada, Australia, the Netherlands, and the United Kingdom, due to potential harmful health effects. While yohimbine hydrochloride was historically an FDA-approved prescription medication for erectile dysfunction, it is now rarely used due to superior alternatives with fewer side effects. Clinical trials on the bark extract itself for any health condition, including topical application, are absent. Severe adverse events reported for yohimbine include tachycardia, hypertension, flushing, sweating, nausea, headaches, anxiety, and restlessness. Individuals with pre-existing conditions such as anxiety, depression, hypertension, hypotension, or PTSD should strictly avoid yohimbine. Overdose or co-administration with other medications can result in serious harm.